NCT01260896

Venlafaxine Hydrochloride 150 mg Extended-Release Capsules Under Fasting Conditions

Randomized, 2-way Crossover, Bioequivalence Study of Venlafaxine Hydrochloride 150 mg Extended-Release Capsules and Effexor® XR 150 mg Extended-Release Capsules Administered as 1 x 150 mg Extended-Release Capsule in Healthy Subjects Under Fasting Conditions.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Teva Pharmaceuticals USA · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The objective of this study was to compare the rate and extent of absorption of venlafaxine hydrochloride 150 mg extended-release capsules (test) versus Effexor® XR (reference) administered as 1 x 150 mg extended-release capsule under fasting conditions.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Venlafaxine Hydrochloride	150 mg Extended-Release Capsule
DRUG	Effexor® XR	150 mg Extended-Release Capsule

Timeline

• Start date: 2002-09-01
• Primary completion: 2002-10-01
• Completion: 2002-10-01
• First posted: 2010-12-15
• Last updated: 2011-02-21
• Results posted: 2011-02-21

Locations

1 site across 1 country: Canada